Ultragenyx Pharmaceutical Inc RARE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RARE is a good fit for your portfolio.
News
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
-
Ultragenyx Pharmaceuticals to Seek Accelerated Approval of Genetic Disease Treatment
-
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
-
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
-
Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
-
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
Trading Information
- Previous Close Price
- $40.21
- Day Range
- $39.65–41.01
- 52-Week Range
- $31.52–54.56
- Bid/Ask
- $39.66 / $43.04
- Market Cap
- $3.70 Bil
- Volume/Avg
- 597,650 / 888,659
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.11
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,276
- Website
- https://www.ultragenyx.com
Comparables
Valuation
|
Metric
|
RARE
|
NBIX
|
SRPT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 25.15 | 141.82 |
Price/Book Value | 24.22 | 5.86 | 14.92 |
Price/Sales | 7.11 | 7.20 | 10.29 |
Price/Cash Flow | — | 24.14 | 97.55 |
Price/Earnings
RARE
NBIX
SRPT
Financial Strength
|
Metric
|
RARE
|
NBIX
|
SRPT
|
|---|---|---|---|
Quick Ratio | 2.09 | 2.33 | 2.97 |
Current Ratio | 2.43 | 2.52 | 4.05 |
Interest Coverage | −8.73 | 98.90 | −1.00 |
Quick Ratio
RARE
NBIX
SRPT
Profitability
|
Metric
|
RARE
|
NBIX
|
SRPT
|
|---|---|---|---|
Return on Assets (Normalized) | −35.51% | 19.40% | 6.50% |
Return on Equity (Normalized) | −299.94% | 27.78% | 25.41% |
Return on Invested Capital (Normalized) | −224.67% | 23.85% | 7.51% |
Return on Assets
RARE
NBIX
SRPT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Nlgfjcbhb | Nptq | $628.7 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nnbmrxkr | Dshtry | $122.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nsssyknp | Wjlbvbm | $114.0 Bil | |||
| Moderna Inc
MRNA
| Tdylmdrzj | Jblld | $45.3 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kbrjhzkg | Ynmhdvy | $31.8 Bil | |||
| argenx SE ADR
ARGX
| Hywcfnvd | Jlyj | $25.9 Bil | |||
| BioNTech SE ADR
BNTX
| Vdmcqsws | Jcq | $19.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Sdbwsqjk | Bslsgd | $15.5 Bil | |||
| United Therapeutics Corp
UTHR
| Fqskzwh | Dfyz | $14.0 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Blmytzclds | Vwxlqdh | $11.6 Bil |